The 10-second takeaway
For the quarter ended March 31 (Q1), ICU Medical beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share dropped.
Margins dropped across the board.
ICU Medical reported revenue of $75.5 million. The five analysts polled by S&P Capital IQ wanted to see revenue of $74.4 million on the same basis. GAAP reported sales were 5.7% higher than the prior-year quarter's $71.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.53. The four earnings estimates compiled by S&P Capital IQ forecast $0.48 per share. GAAP EPS of $0.53 for Q1 were 7.0% lower than the prior-year quarter's $0.57 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 46.3%, 280 basis points worse than the prior-year quarter. Operating margin was 15.1%, 210 basis points worse than the prior-year quarter. Net margin was 10.1%, 120 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $79.6 million. On the bottom line, the average EPS estimate is $0.58.
Next year's average estimate for revenue is $322.5 million. The average EPS estimate is $2.58.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 75 members out of 90 rating the stock outperform, and 15 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give ICU Medical a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ICU Medical is buy, with an average price target of $53.75.
The healthcare investing landscape is littered with also-rans and a few major winners. Is ICU Medical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add ICU Medical to My Watchlist.